Novo Nordisk Alzheimer’s drug trials fail in blow to weight-loss giant 

Reuters was the first to report that Novo Nordisk’s closely watched Alzheimer’s trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, sending the obesity drugmaker’s shares sliding.